Wendy See
About Wendy See
Wendy See is a Scientist in Translational Development at Bristol Myers Squibb, with extensive experience in medical writing, cancer biology, and clinical biomarker research.
Current Role at Bristol Myers Squibb
Wendy See currently serves as a Scientist in Translational Development at Bristol Myers Squibb, working in the San Francisco Bay Area. She provides translational research strategy support for drug development programs across multiple disease areas, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), beta thalassemia, and other myeloid indications. Her role leverages her comprehensive knowledge of cancer biology, including both liquid and solid tumors, molecular oncology, and cancer immunology.
Previous Experience at Bristol Myers Squibb
Prior to her current role, Wendy See was a Senior Medical Writer at Bristol Myers Squibb from 2019 to 2020, based in San Francisco, California. During her tenure, she provided clinical trial publication support, including the preparation of posters, abstracts, oral presentations, and scientific manuscripts for major clients. Her work contributed to the dissemination of clinical trial data and insights.
Medical Writing Experience
Wendy See has extensive experience in medical writing. She worked as a Medical Writer at Celgene from 2018 to 2019 and at Health Interactions from 2017 to 2018. Additionally, she served as a Contract Scientific Writer at the University of California, San Francisco, in 2017. Her work involved preparing biomarker and non-clinical study reports for NDA/MAA submissions and providing independent scientific insights.
Educational Background
Wendy See earned her PhD in Cell Biology from Weill Cornell Graduate School of Medical Sciences and Weill Cornell Medical College between 2004 and 2010. She completed her Master's degree at San Francisco State University from 1999 to 2002 and her Bachelor's degree at the University of California, Santa Barbara, from 1993 to 1998. Her postdoctoral research fellowship was conducted at UCSF from 2010 to 2013. Wendy has a strong academic background and significant research experience.
Expertise in Cancer Biology and Clinical Biomarkers
Wendy See has an in-depth knowledge of cancer biology, focusing on both liquid and solid tumors, molecular oncology, and cancer immunology. She is an expert in clinical biomarker discovery, development, and analysis, including drug mechanism research. Wendy is adept at statistical analysis of experimental data and has a strong publication record in high-profile scientific journals. Her expertise includes understanding therapeutic responses and resistance in cancer cell biology.